Oncol Res Treat. 2017;40(5):294-297. doi: 10.1159/000464353. Epub 2017 Mar 27.
The programmed cell death-1 receptor (PD-1) is an immune checkpoint inhibitor which is expressed on the surface of immune effector cells. It is activated mainly by PD-L1 which can be expressed by all human cells. The PD-1/PD-L1 pathway plays a subtle role in maintaining peripheral T-lymphocyte tolerance and regulating inflammation. In cancer, the expression of PD-L1 seems to be one of the major immune escape mechanisms. Many studies have shown efficacy of blocking PD-1 or PD-L1 with specific antibodies like pembrolizumab or atezulizumab. In breast cancer, potential response was demonstrated in metastatic triple-negative breast cancers.
程序性细胞死亡受体 1（PD-1）是一种免疫检查点抑制剂，表达于免疫效应细胞表面。它主要由 PD-L1 激活，PD-L1 可表达于所有人类细胞。PD-1/PD-L1 通路在维持外周 T 淋巴细胞耐受和调节炎症中发挥微妙作用。在癌症中，PD-L1 的表达似乎是主要的免疫逃逸机制之一。许多研究表明，使用 pembrolizumab 或 atezolizumab 等特异性抗体阻断 PD-1 或 PD-L1 具有疗效。在乳腺癌中，转移性三阴性乳腺癌显示出潜在的应答。
